{"gene":"FASLG","run_date":"2026-06-09T23:54:43","timeline":{"discoveries":[{"year":1995,"finding":"Receptor crosslinking of T-cell hybridomas induces Fas ligand (FasL) expression and upregulates Fas, and the ensuing engagement of Fas by FasL activates the programmed cell death programme; a soluble Fas-immunoglobulin fusion protein selectively blocks cell death but not activation, establishing FasL/Fas interaction as the molecular mechanism of activation-induced T-cell death (AICD).","method":"Soluble Fas-Ig fusion protein blockade, receptor crosslinking assays, T-cell hybridoma death assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal functional rescue with soluble decoy receptor, highly replicated finding, foundational mechanistic paper","pmids":["7530337"],"is_preprint":false},{"year":2007,"finding":"ADAM10 (a disintegrin and metalloprotease) mediates proteolytic shedding of FasL from the cell surface, generating soluble FasL (sFasL) and membrane-bound N-terminal fragments; ADAM10 inhibition elevates FasL surface expression and increases both cytotoxic killing capacity and AICD in primary human T cells.","method":"Pharmacological inhibition, in vitro cleavage assays, loss- and gain-of-function studies in murine embryonic fibroblasts (MEFs), primary human T cell experiments","journal":"Cell death and differentiation","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro cleavage assay combined with genetic KO/KI and pharmacological inhibition in multiple cell types, single lab with orthogonal methods","pmids":["17290285"],"is_preprint":false},{"year":2002,"finding":"The cytosolic polyproline region of CD95L (FasL/CD178) interacts via SH3 domain binding with Grb2, FBP17, and PACSIN2 in T-cell lysates; these interactions are abolished by mutation of the respective SH3 domains and may regulate FasL trafficking and directed expression.","method":"Peptide pulldown from T-cell lysates, peptide mass fingerprinting, co-precipitation with overexpressed constructs, SH3 domain mutagenesis","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-precipitation and mutagenesis in overexpression system, single lab, two orthogonal methods (mass fingerprint + co-IP with mutagenesis)","pmids":["12023017"],"is_preprint":false},{"year":2009,"finding":"Phage display screening of a human SH3 domain library identified Tec kinases and sorting nexins as novel interaction partners of the FasL intracellular proline-rich region; interactions were verified by cellular pulldown experiments.","method":"SH3 domain phage display library screening, cellular pulldown assays","journal":"BMC immunology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — phage display plus confirmatory pulldown, single lab, two methods","pmids":["19807924"],"is_preprint":false},{"year":2010,"finding":"FasL palmitoylation within its transmembrane domain is critical for efficient FasL-mediated killing and for FasL processing by ADAM10; FasL processing occurs preferentially within cholesterol/sphingolipid-rich membrane nanodomains (lipid rafts), and Fas–FasL contact is required for efficient processing.","method":"Palmitoylation assays, ADAM10 cleavage assays, lipid raft fractionation, functional cytotoxicity assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — palmitoylation and membrane fractionation with functional readout, single lab, multiple orthogonal methods","pmids":["21368861"],"is_preprint":false},{"year":2006,"finding":"ERK5 activation promotes cell survival by downregulating FasL expression via a mechanism involving PKB-dependent inhibition of the Forkhead transcription factor Foxo3a; loss of ERK5 or MEK5 leads to increased Foxo3a activity and elevated FasL expression that acts as a positive feedback loop enhancing apoptosis under osmotic stress.","method":"Genetic knockout of erk5 and mek5 in fibroblasts, PKB activity assays, Foxo3a activity assays, FasL expression analysis under osmotic stress","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO with defined molecular pathway (PKB→Foxo3a→FasL), single lab, multiple methods","pmids":["16710360"],"is_preprint":false},{"year":2006,"finding":"MEHP-induced FasL transcription in Sertoli cells is regulated through NF-κB and Sp-1 cis-regulatory elements in the FasL promoter; MEHP exposure increases sTNF-α production, which activates NF-κB and Sp-1 via TNFR1 on Sertoli cells, causing robust FasL upregulation and germ cell apoptosis in a feed-forward mechanism.","method":"Serial deletion FasL promoter-luciferase assays, site-directed mutagenesis, EMSA, chromatin immunoprecipitation, in vitro and in vivo siRNA/TNF-α neutralization experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — promoter deletion + site-directed mutagenesis + EMSA + ChIP + in vivo/in vitro functional assays, single lab with multiple orthogonal rigorous methods","pmids":["17192273"],"is_preprint":false},{"year":2006,"finding":"The glucocorticoid receptor (GR) represses the human FasL promoter by binding to a negative glucocorticoid response element at position -990 that overlaps an NF-κB binding site, competing sterically with NF-κB for DNA binding; this represents a DNA binding-dependent mechanism of GR repression distinct from transrepression.","method":"Promoter-reporter assays, in vitro DNA binding assays, chromatin context binding assays, competition binding experiments","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro DNA binding plus chromatin-context competition assay plus reporter assays, single lab, multiple orthogonal methods","pmids":["16770006"],"is_preprint":false},{"year":2006,"finding":"Active transcription of the FASLG/CD178/TNFSF6 gene in T lymphocytes requires chromatin remodeling at a hypersensitive site (HSS1, -189 to +185), where two precisely positioned nucleosomes are displaced; HSS1 remodeling precedes detectable FasL mRNA accumulation and is blocked by cycloheximide, indicating it is a primary regulatory event independent of DNA methylation or histone deacetylation at this locus.","method":"Indirect end-labeling, DNase I hypersensitivity mapping, micrococcal nuclease and restriction enzyme digestion, cycloheximide inhibition, primary and leukemia T cell comparisons","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — chromatin structure analysis with multiple nuclease probes and functional correlation, single lab","pmids":["16595663"],"is_preprint":false},{"year":2010,"finding":"FasL mRNA is stabilized in activated T cells through binding of the RNA-binding protein HuR to two AU-rich elements (AREs) in the FasL 3'-UTR; HuR knockdown prevents PMA-induced expression of a GFP reporter fused to the FasL 3'-UTR, demonstrating posttranscriptional regulation of FasL by HuR.","method":"Sequence analysis of 3'-UTR, in vitro and ex vivo RNA-protein interaction assays (RIP), HuR knockdown in HEK293 cells, GFP-reporter fused to FasL 3'-UTR","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-binding assay in vitro and ex vivo plus functional reporter knockdown, single lab, two orthogonal methods","pmids":["20675370"],"is_preprint":false},{"year":2016,"finding":"Crystal structure of human FasL in complex with its decoy receptor DcR3 was determined; structure-informed mutations and native glycosylation of recombinant FasL reduce aggregation tendency and significantly enhance FasL-induced apoptosis in Jurkat cells, revealing how aggregation state modulates FasL activity.","method":"X-ray crystallography, recombinant protein production, site-directed mutagenesis, Jurkat cell apoptosis assays","journal":"Structure","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure combined with structure-guided mutagenesis and functional apoptosis assays, single lab with multiple orthogonal methods","pmids":["27806260"],"is_preprint":false},{"year":2013,"finding":"ERα signaling in osteoblasts induces upregulation of MMP3 expression; MMP3 cleaves and solubilizes membrane-bound FasL, and the released soluble FasL induces osteoclast apoptosis; MMP3 inhibition blocks FasL cleavage and osteoclast apoptosis, and ERα-KO osteoblasts show decreased MMP3 but not MMP7 or ADAM10 expression.","method":"EGFP-FasL cleavage assays, MMP3-specific inhibitors, siRNA knockdown of MMP3, ERα-KO mouse-derived osteoblasts, calvarial organ culture, conditioned media soluble FasL ELISA, osteoblast-osteoclast co-culture","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — multiple orthogonal methods (siRNA, KO, inhibitors, ELISA, co-culture) in primary cells and organ culture, single lab","pmids":["22927007"],"is_preprint":false},{"year":2018,"finding":"FasL on platelets directly interacts with FasR (CD95) on red blood cells (RBCs), causing phosphatidylserine (PS) externalization on RBC membranes; this enhances thrombin generation and thrombus formation. Genetic deletion or inhibition of FasL reduces PS exposure, thrombin generation, and arterial thrombosis in vivo.","method":"FasL-/- and FasR-/- mouse models, in vitro platelet-RBC interaction assays, carotid artery injury model, IVC ligation model, flow cytometry, human surgical specimens","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO in multiple in vivo thrombosis models plus in vitro mechanistic assays, replicated across multiple experimental systems","pmids":["29952767"],"is_preprint":false},{"year":2001,"finding":"FADD and Caspase-8 are essential for FasL-induced apoptosis in glioma cells; one sensitive glioma line (D270) can be protected by anti-apoptotic Bcl-2 family members (type II behavior) while another (D645) cannot (type I behavior), demonstrating that FasL-induced apoptosis can proceed via Bcl-2-dependent or Bcl-2-independent pathways depending on cell type.","method":"Panel of seven glioma cell lines, FasL and TRAIL treatment, caspase inhibitor analysis, Bcl-2 overexpression protection assays, cycloheximide sensitization","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic overexpression plus pathway inhibition across multiple cell lines, single lab","pmids":["11593384"],"is_preprint":false},{"year":2011,"finding":"TGF-β3 signaling through Tgfβr2 in the medial edge epithelium (MEE) is required upstream of the FasL-Fas-Caspase extrinsic apoptosis pathway during palatal fusion; inhibition of the FasL-Fas system prevents MEE disappearance and caspase activity, while ectopic FasL rescues apoptosis in Tgfbr2-deficient MEE.","method":"Tgf-β3 and Tgfbr2 conditional knockout mice, FasL/Fas inhibition in palatal organ culture, ectopic FasL protein rescue experiment, caspase activity assays","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (KO + rescue), single lab, multiple methods","pmids":["21593251"],"is_preprint":false},{"year":2010,"finding":"Antigen-specific cytotoxicity of invariant NKT (iNKT) cells in vivo depends almost exclusively on CD95 (Fas)/CD178 (FasL) interaction, correlating with CD1d expression level and TCR affinity for the target glycolipid; this is distinct from NK cells which rely primarily on perforin/granzyme mechanisms.","method":"In vivo cytotoxicity assays in mice, genetic deficiency models (FasL-deficient gld mice), tumor protection experiments, in vitro cytotoxicity with spleen/liver/thymus iNKT cells","journal":"Journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic deficiency model with functional cytotoxicity readout, single lab","pmids":["20660713"],"is_preprint":false},{"year":2000,"finding":"Neurons express FasL protein and mRNA; neuronal FasL induces apoptosis of co-cultured CD4+ encephalitogenic T cells, and antibodies blocking neuronal FasL protect T cells from death in co-culture, identifying neuronal FasL as a mechanism for eliminating inflammatory T cells in neuroinflammation.","method":"In situ hybridization, immunohistochemistry, hippocampal neuron/T-cell co-culture, FasL-blocking antibody experiments","journal":"Brain pathology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — blocking antibody rescue in co-culture plus in vivo localization, single lab","pmids":["10885654"],"is_preprint":false},{"year":2014,"finding":"Human B cell-derived lymphoblastoid cell lines (LCL) constitutively produce FasL retained intracellularly in secretory lysosomes and secreted via exosomes as MHCII+FasL+ vesicles; these LCL-derived exosomes induce antigen-specific apoptosis in autologous CD4+ T cells.","method":"Flow cytometry, bead-based exosome capture assay, two independent apoptosis assays with LCL-derived exosomes and autologous CD4+ T cells","journal":"Frontiers in immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — exosome isolation with functional apoptosis assay confirmed by two independent methods, single lab","pmids":["24765093"],"is_preprint":false},{"year":2018,"finding":"High-dose osteocalcin (GluOC) activates GPRC6A→cAMP→PKA→CREB→p300→FoxO1 signaling, leading to FasL upregulation at the plasma membrane of adipocytes; FasL engagement of Fas on neighboring adipocytes triggers MLKL phosphorylation/homotrimerization and necroptosis.","method":"Signaling pathway dissection (CREB/p300/FoxO1 activation assays), FasL expression and membrane localization analysis, MLKL phosphorylation and homotrimerization assays, 3T3-L1 adipocyte model","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — defined signaling pathway with multiple downstream readouts, single lab, multiple biochemical assays","pmids":["30546087"],"is_preprint":false},{"year":2021,"finding":"DNA origami nanoagents presenting FasL in a hexagonal arrangement with 10 nm inter-molecular spacing mimic the predicted hexagonal DISC architecture and induce fastest and most efficient apoptosis signaling; reduced FasL number, altered spacing, or increased coupling flexibility impairs signaling, defining molecular geometry requirements for FasL-mediated death receptor activation.","method":"DNA origami scaffold engineering with defined FasL arrangements, cell apoptosis kinetics assays, comparison of geometric configurations","journal":"Small","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — reconstituted nanoscale signaling platform with systematic geometric variation and functional readout, single lab","pmids":["34057291"],"is_preprint":false},{"year":2012,"finding":"Complete FasL deficiency due to a homozygous null FASLG mutation (F87fs×95) causes autoimmune lymphoproliferative syndrome (ALPS) with absent plasma FasL, normal FAS-induced apoptosis, and defective reactivation-induced cell death, establishing that FasL is non-redundantly required for AICD in vivo.","method":"FASLG gene sequencing, Western blotting for FasL expression, FAS-induced apoptosis assay, reactivation-induced cell death (AICD) test, plasma FasL ELISA","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — human loss-of-function with multiple orthogonal assays and clear functional consequence, replicated pattern with prior mouse gld data","pmids":["22857792"],"is_preprint":false},{"year":2001,"finding":"Downregulation of FasL surface expression on activated T cells proceeds via endocytosis (not metalloprotease shedding in this context); cytochalasin, sodium azide, deoxyglucose, and low temperature (endocytosis inhibitors) prevented FasL loss, while the metalloprotease inhibitor KB8301 had no effect on FasL loss or AICD in these T cells.","method":"Flow cytometry of FasL surface expression, endocytosis inhibitors, metalloprotease inhibitor KB8301, IL-2-stimulated T cells","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with multiple inhibitor classes, single lab","pmids":["11529932"],"is_preprint":false},{"year":2012,"finding":"HBx activates FasL expression and mediates HepG2 cell apoptosis through a MLK3→MKK7→JNK signaling module; JNK inhibitor SP600125 and MLK3 inhibitor K252a each blocked FasL upregulation and reduced apoptosis in HBx-expressing cells.","method":"HBx expression vector transfection, siRNA knockdown, Western blotting for FasL and signaling intermediates, JNK and MLK3 inhibitors, apoptosis rate measurement","journal":"World journal of gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis with specific kinase inhibitors and genetic KD, single lab","pmids":["22509080"],"is_preprint":false},{"year":2018,"finding":"TNFα sensitizes hepatocytes to FasL-induced apoptosis by transcriptionally upregulating Fas surface expression via the NF-κB pathway (p65 subunit); genetic deletion, dominant-negative inhibition, or shRNA knockdown of p65 reduces Fas expression and prevents TNFα-induced sensitization to FasL-mediated cell death both in vitro and in vivo (via hydrodynamic p65 shRNA injection).","method":"Primary hepatocytes and cell lines, p65 genetic knockout, dominant-negative inhibition, shRNA knockdown, hydrodynamic tail vein injection in mice, Fas surface expression assays","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion plus dominant-negative plus shRNA confirmed both in vitro and in vivo, multiple orthogonal approaches","pmids":["30185788"],"is_preprint":false}],"current_model":"FASLG (FasL/CD178/CD95L) is a type II transmembrane protein of the TNF superfamily that induces apoptosis in Fas (CD95)-bearing target cells; its surface expression is tightly regulated by ADAM10-mediated ectodomain shedding (modulated by palmitoylation and lipid raft localization), endocytic internalization, transcriptional control through NF-κB, Sp-1, and GR competing at the promoter, and post-transcriptional stabilization by HuR; its intracellular polyproline region serves as a docking platform for SH3-domain proteins (Grb2, FBP17, PACSIN2, Tec kinases, sorting nexins) that regulate its trafficking and potential reverse signaling; optimal FasL-induced DISC assembly requires hexagonal receptor geometry at ~10 nm spacing; proteases MMP3 and ADAM10 generate soluble FasL that can trigger osteoclast and other cell apoptosis; FasL mediates AICD of T cells, iNKT cytotoxicity, neuronal elimination of inflammatory T cells, and platelet-RBC procoagulant signaling, and complete loss-of-function mutations cause autoimmune lymphoproliferative syndrome in humans."},"narrative":{"mechanistic_narrative":"FASLG (FasL/CD178/CD95L) is a type II transmembrane TNF-superfamily ligand that triggers apoptosis in Fas-bearing cells and is the non-redundant effector of activation-induced cell death (AICD) in T lymphocytes [PMID:7530337, PMID:22857792]; its homozygous null mutation causes human autoimmune lymphoproliferative syndrome with intact Fas-induced apoptosis but defective reactivation-induced death [PMID:22857792]. Productive death-signaling depends on ligand geometry: hexagonal FasL presentation at ~10 nm spacing drives fastest DISC-mediated apoptosis, and reduced ligand number or altered spacing impairs signaling [PMID:34057291], while aggregation state (modulated by glycosylation and the decoy receptor DcR3) tunes apoptotic potency [PMID:27806260]. Downstream, FADD and caspase-8 execute killing, which proceeds through Bcl-2-dependent (type II) or Bcl-2-independent (type I) routes depending on target cell [PMID:11593384]. FasL surface availability is governed by proteolytic shedding by ADAM10 — favored within palmitoylation-dependent lipid-raft nanodomains and requiring Fas–FasL contact — which generates soluble FasL and limits cytotoxicity and AICD [PMID:17290285, PMID:21368861], by an alternative MMP3-mediated cleavage downstream of osteoblast ERα signaling that solubilizes FasL to kill osteoclasts [PMID:22927007], and by endocytic internalization independent of metalloprotease shedding [PMID:11529932]. Expression is controlled at multiple levels: chromatin remodeling at the HSS1 promoter site [PMID:16595663], transcriptional activation through NF-κB and Sp-1 and repression by the glucocorticoid receptor competing for an overlapping site [PMID:17192273, PMID:16770006], and post-transcriptional stabilization of FasL mRNA by HuR at 3'-UTR AU-rich elements [PMID:20675370]. Beyond classical cytotoxicity, FasL mediates iNKT-cell killing [PMID:20660713], neuronal elimination of inflammatory T cells [PMID:10885654], exosome-delivered apoptosis of CD4+ T cells [PMID:24765093], adipocyte necroptosis [PMID:30546087], and platelet–red-blood-cell procoagulant signaling that promotes thrombosis [PMID:29952767]. The intracellular polyproline region binds SH3-domain proteins (Grb2, FBP17, PACSIN2, Tec kinases, sorting nexins), implicated in trafficking and potential reverse signaling [PMID:12023017, PMID:19807924].","teleology":[{"year":1995,"claim":"Established that FasL engagement of Fas is the molecular trigger of activation-induced T-cell death, defining the ligand-receptor axis underlying peripheral immune homeostasis.","evidence":"Soluble Fas-Ig decoy blockade and receptor crosslinking in T-cell hybridoma death assays","pmids":["7530337"],"confidence":"High","gaps":["Did not resolve the structural geometry of receptor engagement","Did not address regulation of FasL surface levels"]},{"year":2000,"claim":"Extended FasL effector function beyond lymphocytes by showing neurons use FasL to kill encephalitogenic T cells, framing FasL as a tissue immune-privilege mechanism.","evidence":"In situ hybridization, IHC, and FasL-blocking antibody rescue in neuron/T-cell co-culture","pmids":["10885654"],"confidence":"Medium","gaps":["Co-culture model, not in vivo neuroinflammation","Mechanism of neuronal FasL regulation not addressed"]},{"year":2001,"claim":"Resolved that downstream apoptosis requires FADD and caspase-8 and can be Bcl-2-dependent or independent, defining type I/type II FasL death pathways.","evidence":"Glioma cell-line panel with Bcl-2 overexpression and caspase inhibition","pmids":["11593384"],"confidence":"Medium","gaps":["Cell-type basis for type I vs type II behavior not molecularly explained"]},{"year":2001,"claim":"Identified endocytosis, rather than metalloprotease shedding, as a route for FasL surface downregulation in activated T cells, revealing context-specific control of ligand availability.","evidence":"Endocytosis vs metalloprotease inhibitor panel on IL-2-stimulated T cells, flow cytometry","pmids":["11529932"],"confidence":"Medium","gaps":["Endocytic machinery not identified","Apparent conflict with later ADAM10 shedding data unresolved by context"]},{"year":2002,"claim":"Showed the intracellular polyproline region of FasL recruits SH3-domain adaptors, opening the possibility of trafficking control and reverse signaling.","evidence":"Peptide pulldown, mass fingerprinting, and SH3 mutagenesis in T-cell lysates/overexpression","pmids":["12023017"],"confidence":"Medium","gaps":["Overexpression-based interactions","Functional consequence for trafficking not demonstrated"]},{"year":2006,"claim":"Mapped multiple transcriptional and chromatin control points (HSS1 remodeling, NF-κB/Sp-1 activation, GR repression, ERK5/Foxo3a) defining how FasL expression is set.","evidence":"Promoter-reporter, EMSA, ChIP, nucleosome mapping, and kinase/transcription-factor genetic perturbation across multiple systems","pmids":["16595663","17192273","16770006","16710360"],"confidence":"Medium","gaps":["Largely single-system promoter studies","Cross-talk integration among these inputs not established"]},{"year":2007,"claim":"Identified ADAM10 as the protease shedding FasL, establishing that ectodomain cleavage limits cytotoxic and AICD activity.","evidence":"In vitro cleavage, MEF KO/KI, pharmacological inhibition, primary human T cells","pmids":["17290285"],"confidence":"High","gaps":["Did not define spatial/membrane control of cleavage"]},{"year":2010,"claim":"Linked FasL palmitoylation and lipid-raft localization to ADAM10 processing and killing efficiency, and added HuR-mediated mRNA stabilization as a post-transcriptional control.","evidence":"Palmitoylation/raft fractionation with cytotoxicity assays; RIP and 3'-UTR reporter with HuR knockdown","pmids":["21368861","20675370"],"confidence":"Medium","gaps":["Palmitoyltransferase not identified","HuR work largely in HEK293 reporter context"]},{"year":2010,"claim":"Demonstrated that iNKT cytotoxicity depends almost exclusively on the Fas/FasL axis, distinguishing it from perforin-based NK killing.","evidence":"In vivo cytotoxicity in FasL-deficient gld mice with tumor protection assays","pmids":["20660713"],"confidence":"Medium","gaps":["Mechanism of FasL polarization at the iNKT synapse not addressed"]},{"year":2011,"claim":"Placed FasL-Fas-caspase apoptosis downstream of TGF-β3/Tgfbr2 signaling in epithelial fusion, showing a developmental role via genetic epistasis.","evidence":"Tgfbr2 conditional KO with FasL/Fas inhibition and ectopic FasL rescue in palatal organ culture","pmids":["21593251"],"confidence":"Medium","gaps":["Transcriptional link from TGF-β3 to FasL not defined"]},{"year":2012,"claim":"Provided the definitive human genetic proof that FasL is non-redundantly required for AICD, as null mutation causes ALPS with defective reactivation-induced death.","evidence":"FASLG sequencing, Western blot, FAS-induced apoptosis and AICD assays, plasma FasL ELISA in patient","pmids":["22857792"],"confidence":"High","gaps":["Single homozygous case","Does not address partial loss-of-function phenotypes"]},{"year":2013,"claim":"Identified MMP3 as an ERα-induced alternative protease that solubilizes FasL to drive osteoclast apoptosis, broadening the proteolytic regulation of FasL beyond ADAM10.","evidence":"EGFP-FasL cleavage, MMP3 inhibitors/siRNA, ERα-KO osteoblasts, co-culture and soluble FasL ELISA","pmids":["22927007"],"confidence":"High","gaps":["Relative contribution of MMP3 vs ADAM10 across tissues unclear"]},{"year":2014,"claim":"Showed FasL is delivered via exosomes as MHCII+FasL+ vesicles capable of antigen-specific T-cell killing, adding a secreted delivery mode.","evidence":"Flow cytometry, bead-based exosome capture, two apoptosis assays with LCL exosomes and autologous CD4+ T cells","pmids":["24765093"],"confidence":"Medium","gaps":["In vivo relevance of exosomal FasL not established"]},{"year":2016,"claim":"Determined the FasL–DcR3 structure and showed aggregation state controls apoptotic potency, connecting molecular architecture to activity.","evidence":"X-ray crystallography with structure-guided mutagenesis and Jurkat apoptosis assays","pmids":["27806260"],"confidence":"High","gaps":["Did not directly resolve the apoptosis-competent membrane DISC geometry"]},{"year":2018,"claim":"Expanded FasL into procoagulant and metabolic biology—platelet FasL drives RBC PS exposure and thrombosis, and osteocalcin-induced FasL triggers adipocyte necroptosis—and showed TNFα/NF-κB sensitizes hepatocytes by upregulating Fas.","evidence":"FasL/FasR KO thrombosis models, GPRC6A→CREB→FoxO1 signaling with MLKL readouts, p65 genetic/shRNA perturbation in hepatocytes in vitro and in vivo","pmids":["29952767","30546087","30185788"],"confidence":"High","gaps":["Diverse systems with limited cross-validation","Switch between apoptotic and necroptotic outcomes not mechanistically unified"]},{"year":2021,"claim":"Defined the molecular geometry requirements for FasL signaling, showing hexagonal ~10 nm ligand spacing maximizes apoptosis, linking nanoscale ligand arrangement to DISC assembly.","evidence":"DNA origami scaffolds with systematic FasL spacing/number variation and apoptosis kinetics","pmids":["34057291"],"confidence":"Medium","gaps":["Predicted hexagonal DISC architecture inferred functionally, not structurally observed in cells"]},{"year":null,"claim":"How the competing fates of FasL — surface presentation, ADAM10/MMP3 shedding, endocytosis, and exosomal export — are integrated in a single cell to set output (apoptosis vs necroptosis vs reverse signaling) remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model coordinating trafficking, cleavage, and SH3-adaptor reverse signaling","Physiological role of intracellular polyproline interactions undemonstrated","Determinants selecting apoptotic vs necroptotic downstream outcome unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[0,10,19]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,12]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[1,4,18,21]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[17]}],"pathway":[{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[0,13,18]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,15,16,20]},{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[12]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[6,7,8]}],"complexes":["DISC"],"partners":["FAS","ADAM10","MMP3","DCR3","GRB2","FBP17","PACSIN2","HUR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P48023","full_name":"Tumor necrosis factor ligand superfamily member 6","aliases":["Apoptosis antigen ligand","APTL","CD95 ligand","CD95-L","Fas antigen ligand","Fas ligand","FasL"],"length_aa":281,"mass_kda":31.5,"function":"Cytokine that binds to TNFRSF6/FAS, a receptor that transduces the apoptotic signal into cells (PubMed:26334989, PubMed:9228058). Involved in cytotoxic T-cell-mediated apoptosis, natural killer cell-mediated apoptosis and in T-cell development (PubMed:7528780, PubMed:9228058, PubMed:9427603). Initiates fratricidal/suicidal activation-induced cell death (AICD) in antigen-activated T-cells contributing to the termination of immune responses (By similarity). TNFRSF6/FAS-mediated apoptosis also has a role in the induction of peripheral tolerance (By similarity). Binds to TNFRSF6B/DcR3, a decoy receptor that blocks apoptosis (PubMed:27806260) Induces FAS-mediated activation of NF-kappa-B, initiating non-apoptotic signaling pathways (By similarity). Can induce apoptosis but does not appear to be essential for this process (PubMed:27806260) Cytoplasmic form induces gene transcription inhibition","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/P48023/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FASLG","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FASLG","total_profiled":1310},"omim":[{"mim_id":"620293","title":"TMEM9 DOMAIN FAMILY, MEMBER B; TMEM9B","url":"https://www.omim.org/entry/620293"},{"mim_id":"616729","title":"OLFACTORY RECEPTOR, FAMILY 2, SUBFAMILY W, MEMBER 3; OR2W3","url":"https://www.omim.org/entry/616729"},{"mim_id":"301078","title":"IMMUNODEFICIENCY 98 WITH AUTOINFLAMMATION, X-LINKED; IMD98","url":"https://www.omim.org/entry/301078"},{"mim_id":"211980","title":"LUNG CANCER","url":"https://www.omim.org/entry/211980"},{"mim_id":"163730","title":"NITRIC OXIDE SYNTHASE 2; NOS2","url":"https://www.omim.org/entry/163730"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":5.3}],"url":"https://www.proteinatlas.org/search/FASLG"},"hgnc":{"alias_symbol":["FasL","CD178"],"prev_symbol":["APT1LG1","TNFSF6"]},"alphafold":{"accession":"P48023","domains":[{"cath_id":"2.60.120.40","chopping":"145-195_211-226_243-279","consensus_level":"high","plddt":96.0808,"start":145,"end":279}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P48023","model_url":"https://alphafold.ebi.ac.uk/files/AF-P48023-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P48023-F1-predicted_aligned_error_v6.png","plddt_mean":80.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FASLG","jax_strain_url":"https://www.jax.org/strain/search?query=FASLG"},"sequence":{"accession":"P48023","fasta_url":"https://rest.uniprot.org/uniprotkb/P48023.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P48023/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P48023"}},"corpus_meta":[{"pmid":"7530337","id":"PMC_7530337","title":"Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation.","date":"1995","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/7530337","citation_count":1391,"is_preprint":false},{"pmid":"8579749","id":"PMC_8579749","title":"Fas and FasL in the homeostatic regulation of immune responses.","date":"1995","source":"Immunology today","url":"https://pubmed.ncbi.nlm.nih.gov/8579749","citation_count":505,"is_preprint":false},{"pmid":"15240787","id":"PMC_15240787","title":"Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma.","date":"2004","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/15240787","citation_count":169,"is_preprint":false},{"pmid":"28424702","id":"PMC_28424702","title":"Dual Role of Fas/FasL-Mediated Signal in Peripheral Immune Tolerance.","date":"2017","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/28424702","citation_count":165,"is_preprint":false},{"pmid":"17290285","id":"PMC_17290285","title":"ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death.","date":"2007","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/17290285","citation_count":161,"is_preprint":false},{"pmid":"15607805","id":"PMC_15607805","title":"Impact of FASL-induced apoptosis in the elimination of tumor cells by NK cells.","date":"2005","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15607805","citation_count":124,"is_preprint":false},{"pmid":"22239437","id":"PMC_22239437","title":"Targeting the Fas/FasL signaling pathway in cancer therapy.","date":"2012","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/22239437","citation_count":121,"is_preprint":false},{"pmid":"20660713","id":"PMC_20660713","title":"Antigen-specific cytotoxicity by invariant NKT cells in vivo is CD95/CD178-dependent and is correlated with antigenic potency.","date":"2010","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/20660713","citation_count":114,"is_preprint":false},{"pmid":"12147205","id":"PMC_12147205","title":"The biological role of the Fas/FasL system during tumor formation and progression.","date":"2002","source":"Seminars in cancer biology","url":"https://pubmed.ncbi.nlm.nih.gov/12147205","citation_count":100,"is_preprint":false},{"pmid":"11593384","id":"PMC_11593384","title":"Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.","date":"2001","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/11593384","citation_count":92,"is_preprint":false},{"pmid":"10885654","id":"PMC_10885654","title":"Neuronal FasL induces cell death of encephalitogenic T lymphocytes.","date":"2000","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/10885654","citation_count":86,"is_preprint":false},{"pmid":"24765093","id":"PMC_24765093","title":"Human B Cell-Derived Lymphoblastoid Cell Lines Constitutively Produce Fas Ligand and Secrete MHCII(+)FasL(+) Killer Exosomes.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24765093","citation_count":82,"is_preprint":false},{"pmid":"31072029","id":"PMC_31072029","title":"TRAIL and FasL Functions in Cancer and Autoimmune Diseases: Towards an Increasing Complexity.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31072029","citation_count":78,"is_preprint":false},{"pmid":"11991678","id":"PMC_11991678","title":"The role of Fas and FasL as mediators of anticancer chemotherapy.","date":"2001","source":"Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/11991678","citation_count":76,"is_preprint":false},{"pmid":"29952767","id":"PMC_29952767","title":"Platelet-RBC interaction mediated by FasL/FasR induces procoagulant activity important for thrombosis.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29952767","citation_count":75,"is_preprint":false},{"pmid":"9761749","id":"PMC_9761749","title":"Expression of Fas (CD95) and FasL (CD95L) in human airway epithelium.","date":"1998","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9761749","citation_count":74,"is_preprint":false},{"pmid":"21126798","id":"PMC_21126798","title":"Insights into the molecular regulation of FasL (CD178) biology.","date":"2010","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21126798","citation_count":61,"is_preprint":false},{"pmid":"25394756","id":"PMC_25394756","title":"MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25394756","citation_count":61,"is_preprint":false},{"pmid":"22927007","id":"PMC_22927007","title":"ERα signaling regulates MMP3 expression to induce FasL cleavage and osteoclast apoptosis.","date":"2013","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/22927007","citation_count":61,"is_preprint":false},{"pmid":"34057291","id":"PMC_34057291","title":"Nanoscale FasL Organization on DNA Origami to Decipher Apoptosis Signal Activation in Cells.","date":"2021","source":"Small (Weinheim an der Bergstrasse, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34057291","citation_count":61,"is_preprint":false},{"pmid":"16148053","id":"PMC_16148053","title":"Hyperoxia-induced apoptosis and Fas/FasL expression in lung epithelial cells.","date":"2005","source":"American journal of physiology. Lung cellular and molecular physiology","url":"https://pubmed.ncbi.nlm.nih.gov/16148053","citation_count":61,"is_preprint":false},{"pmid":"22961755","id":"PMC_22961755","title":"TRAIL but not FasL and TNFα, regulates IL-33 expression in murine hepatocytes during acute hepatitis.","date":"2012","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22961755","citation_count":58,"is_preprint":false},{"pmid":"12787569","id":"PMC_12787569","title":"Biology of FasL.","date":"2003","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/12787569","citation_count":52,"is_preprint":false},{"pmid":"16710360","id":"PMC_16710360","title":"Activation of extracellular signal-regulated protein kinase 5 downregulates FasL upon osmotic stress.","date":"2006","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/16710360","citation_count":52,"is_preprint":false},{"pmid":"33980818","id":"PMC_33980818","title":"Fas/FasL mediates NF-κBp65/PUMA-modulated hepatocytes apoptosis via autophagy to drive liver fibrosis.","date":"2021","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/33980818","citation_count":52,"is_preprint":false},{"pmid":"19760067","id":"PMC_19760067","title":"The role of FasL and Fas in health and disease.","date":"2009","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/19760067","citation_count":51,"is_preprint":false},{"pmid":"15339846","id":"PMC_15339846","title":"Fas-ligand (CD178) and TRAIL synergistically induce apoptosis of CD40-activated chronic lymphocytic leukemia B cells.","date":"2004","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/15339846","citation_count":51,"is_preprint":false},{"pmid":"17192273","id":"PMC_17192273","title":"Transcriptional regulation of FasL expression and participation of sTNF-alpha in response to sertoli cell injury.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17192273","citation_count":51,"is_preprint":false},{"pmid":"11595539","id":"PMC_11595539","title":"Apoptosis induced by FasL and TRAIL/Apo2L in the pathogenesis of thyroid diseases.","date":"2001","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/11595539","citation_count":49,"is_preprint":false},{"pmid":"30185788","id":"PMC_30185788","title":"TNFα sensitizes hepatocytes to FasL-induced apoptosis by NFκB-mediated Fas upregulation.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30185788","citation_count":49,"is_preprint":false},{"pmid":"11054182","id":"PMC_11054182","title":"Fas and Fas-L expression in Huntington's disease and Parkinson's disease.","date":"2000","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/11054182","citation_count":49,"is_preprint":false},{"pmid":"26826505","id":"PMC_26826505","title":"Downregulation of let-7e-5p contributes to endothelial progenitor cell dysfunction in deep vein thrombosis via targeting FASLG.","date":"2015","source":"Thrombosis research","url":"https://pubmed.ncbi.nlm.nih.gov/26826505","citation_count":49,"is_preprint":false},{"pmid":"16770006","id":"PMC_16770006","title":"Competition between glucocorticoid receptor and NFkappaB for control of the human FasL promoter.","date":"2006","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/16770006","citation_count":46,"is_preprint":false},{"pmid":"11965496","id":"PMC_11965496","title":"Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians.","date":"2002","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/11965496","citation_count":44,"is_preprint":false},{"pmid":"21368861","id":"PMC_21368861","title":"Palmitoylation of human FasL modulates its cell death-inducing function.","date":"2010","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/21368861","citation_count":44,"is_preprint":false},{"pmid":"31225740","id":"PMC_31225740","title":"miR-21-5p Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting FASLG.","date":"2019","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/31225740","citation_count":43,"is_preprint":false},{"pmid":"25381758","id":"PMC_25381758","title":"Stem Cell Therapies for Intervertebral Disc Degeneration: Immune Privilege Reinforcement by Fas/FasL Regulating Machinery.","date":"2015","source":"Current stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25381758","citation_count":43,"is_preprint":false},{"pmid":"30458362","id":"PMC_30458362","title":"Localized immune tolerance from FasL-functionalized PLG scaffolds.","date":"2018","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/30458362","citation_count":43,"is_preprint":false},{"pmid":"30546087","id":"PMC_30546087","title":"Osteocalcin triggers Fas/FasL-mediated necroptosis in adipocytes via activation of p300.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30546087","citation_count":43,"is_preprint":false},{"pmid":"28013316","id":"PMC_28013316","title":"Inhibition of MicroRNA-149-5p Induces Apoptosis of Acute Myeloid Leukemia Cell Line THP-1 by Targeting Fas Ligand (FASLG).","date":"2016","source":"Medical science monitor : international medical journal of experimental and clinical research","url":"https://pubmed.ncbi.nlm.nih.gov/28013316","citation_count":43,"is_preprint":false},{"pmid":"22857792","id":"PMC_22857792","title":"Autoimmune lymphoproliferative syndrome caused by a homozygous null FAS ligand (FASLG) mutation.","date":"2012","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/22857792","citation_count":42,"is_preprint":false},{"pmid":"32036560","id":"PMC_32036560","title":"FasL-PDPK1 Pathway Promotes the Cytotoxicity of CD8+ T Cells During Ischemic Stroke.","date":"2020","source":"Translational stroke research","url":"https://pubmed.ncbi.nlm.nih.gov/32036560","citation_count":42,"is_preprint":false},{"pmid":"10440512","id":"PMC_10440512","title":"New kids in the block: the role of FasL and Fas in kidney damage.","date":"1999","source":"Journal of nephrology","url":"https://pubmed.ncbi.nlm.nih.gov/10440512","citation_count":40,"is_preprint":false},{"pmid":"12023017","id":"PMC_12023017","title":"Identification of interaction partners of the cytosolic polyproline region of CD95 ligand (CD178).","date":"2002","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/12023017","citation_count":39,"is_preprint":false},{"pmid":"16158329","id":"PMC_16158329","title":"Genetic polymorphisms of Fas (CD95) and Fas ligand (CD178) influence the rise in CD4+ T cell count after antiretroviral therapy in drug-naïve HIV-positive patients.","date":"2005","source":"Immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/16158329","citation_count":39,"is_preprint":false},{"pmid":"11529932","id":"PMC_11529932","title":"The regulation of FasL expression during activation-induced cell death (AICD).","date":"2001","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11529932","citation_count":38,"is_preprint":false},{"pmid":"21910009","id":"PMC_21910009","title":"Fas/FasL pathway-mediated alveolar macrophage apoptosis involved in human silicosis.","date":"2011","source":"Apoptosis : an international journal on programmed cell death","url":"https://pubmed.ncbi.nlm.nih.gov/21910009","citation_count":38,"is_preprint":false},{"pmid":"27806260","id":"PMC_27806260","title":"Crystal Structure of the Complex of Human FasL and Its Decoy Receptor DcR3.","date":"2016","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/27806260","citation_count":38,"is_preprint":false},{"pmid":"34957697","id":"PMC_34957697","title":"FasL+ PD-L2+ Identifies a Novel Immunosuppressive Neutrophil Population in Human Gastric Cancer That Promotes Disease Progression.","date":"2021","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/34957697","citation_count":37,"is_preprint":false},{"pmid":"16155003","id":"PMC_16155003","title":"The C terminus of HIV-1 Tat modulates the extent of CD178-mediated apoptosis of T cells.","date":"2005","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16155003","citation_count":37,"is_preprint":false},{"pmid":"19832988","id":"PMC_19832988","title":"Role of the Fas/FasL pathway in HIV or SIV disease.","date":"2009","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/19832988","citation_count":36,"is_preprint":false},{"pmid":"15120186","id":"PMC_15120186","title":"Regulation of FasL expression in natural killer cells.","date":"2004","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15120186","citation_count":36,"is_preprint":false},{"pmid":"11918688","id":"PMC_11918688","title":"Immune privilege and FasL: two ways to inactivate effector cytotoxic T lymphocytes by FasL-expressing cells.","date":"2002","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11918688","citation_count":35,"is_preprint":false},{"pmid":"22509080","id":"PMC_22509080","title":"HBx activates FasL and mediates HepG2 cell apoptosis through MLK3-MKK7-JNKs signal module.","date":"2012","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22509080","citation_count":34,"is_preprint":false},{"pmid":"24821435","id":"PMC_24821435","title":"miR-21 regulates N-methyl-N-nitro-N'-nitrosoguanidine-induced gastric tumorigenesis by targeting FASLG and BTG2.","date":"2014","source":"Toxicology letters","url":"https://pubmed.ncbi.nlm.nih.gov/24821435","citation_count":34,"is_preprint":false},{"pmid":"11500826","id":"PMC_11500826","title":"The Fas-FasL death receptor and PI3K pathways independently regulate monocyte homeostasis.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11500826","citation_count":33,"is_preprint":false},{"pmid":"16543918","id":"PMC_16543918","title":"FasL gene therapy: a new therapeutic modality for head and neck cancer.","date":"2006","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/16543918","citation_count":32,"is_preprint":false},{"pmid":"29453321","id":"PMC_29453321","title":"Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.","date":"2018","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/29453321","citation_count":32,"is_preprint":false},{"pmid":"10797617","id":"PMC_10797617","title":"Regulation of Fas and FasL expression on rat Schwann cells.","date":"2000","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/10797617","citation_count":32,"is_preprint":false},{"pmid":"20967287","id":"PMC_20967287","title":"Systemic FasL and TRAIL neutralisation reduce leishmaniasis induced skin ulceration.","date":"2010","source":"PLoS neglected tropical diseases","url":"https://pubmed.ncbi.nlm.nih.gov/20967287","citation_count":31,"is_preprint":false},{"pmid":"24938700","id":"PMC_24938700","title":"Fas/FasL in the immune pathogenesis of severe aplastic anemia.","date":"2014","source":"Genetics and molecular research : GMR","url":"https://pubmed.ncbi.nlm.nih.gov/24938700","citation_count":30,"is_preprint":false},{"pmid":"34526992","id":"PMC_34526992","title":"Fas/FasL Contributes to HSV-1 Brain Infection and Neuroinflammation.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34526992","citation_count":29,"is_preprint":false},{"pmid":"9922038","id":"PMC_9922038","title":"On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.","date":"1998","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9922038","citation_count":29,"is_preprint":false},{"pmid":"20185587","id":"PMC_20185587","title":"Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20185587","citation_count":28,"is_preprint":false},{"pmid":"37865305","id":"PMC_37865305","title":"CD95 (Fas) and CD95L (FasL)-mediated non-canonical signaling pathways.","date":"2023","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37865305","citation_count":27,"is_preprint":false},{"pmid":"25812467","id":"PMC_25812467","title":"Cutting edge: FasL(+) immune cells promote resolution of fibrosis.","date":"2015","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/25812467","citation_count":26,"is_preprint":false},{"pmid":"25481649","id":"PMC_25481649","title":"Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?","date":"2014","source":"Cytokine","url":"https://pubmed.ncbi.nlm.nih.gov/25481649","citation_count":26,"is_preprint":false},{"pmid":"21593251","id":"PMC_21593251","title":"Tgf-beta-mediated FasL-Fas-Caspase pathway is crucial during palatogenesis.","date":"2011","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/21593251","citation_count":26,"is_preprint":false},{"pmid":"18383830","id":"PMC_18383830","title":"Polymorphisms of death pathway genes FAS and FASL and risk of premalignant gastric lesions.","date":"2008","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18383830","citation_count":25,"is_preprint":false},{"pmid":"19132323","id":"PMC_19132323","title":"FasL expression and reverse signalling.","date":"2009","source":"Results and problems in cell differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/19132323","citation_count":24,"is_preprint":false},{"pmid":"11321234","id":"PMC_11321234","title":"Fas-FasL in Hashimoto's thyroiditis.","date":"2001","source":"Journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11321234","citation_count":24,"is_preprint":false},{"pmid":"26334989","id":"PMC_26334989","title":"Decreased activation-induced cell death by EBV-transformed B-cells from a patient with autoimmune lymphoproliferative syndrome caused by a novel FASLG mutation.","date":"2015","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/26334989","citation_count":23,"is_preprint":false},{"pmid":"16212646","id":"PMC_16212646","title":"Perforin and Fas/FasL cytolytic pathways at the maternal-fetal interface.","date":"2005","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/16212646","citation_count":23,"is_preprint":false},{"pmid":"12794109","id":"PMC_12794109","title":"CTLA-4. FasL induces alloantigen-specific hyporesponsiveness.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12794109","citation_count":23,"is_preprint":false},{"pmid":"25873756","id":"PMC_25873756","title":"Fas/FasL pathway participates in regulation of antiviral and inflammatory response during mousepox infection of lungs.","date":"2015","source":"Mediators of inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/25873756","citation_count":22,"is_preprint":false},{"pmid":"28682425","id":"PMC_28682425","title":"Fas/FasL induces myocardial cell apoptosis in myocardial ischemia-reperfusion rat model.","date":"2017","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28682425","citation_count":22,"is_preprint":false},{"pmid":"32905906","id":"PMC_32905906","title":"Molecular mechanisms of FasL-mediated 'reverse-signaling'.","date":"2020","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32905906","citation_count":21,"is_preprint":false},{"pmid":"34889164","id":"PMC_34889164","title":"Long non-coding RNA CASC7 suppresses malignant behaviors of breast cancer by regulating miR-21-5p/FASLG axis.","date":"2021","source":"Bioengineered","url":"https://pubmed.ncbi.nlm.nih.gov/34889164","citation_count":21,"is_preprint":false},{"pmid":"30286163","id":"PMC_30286163","title":"Fas/FasL pathway and cytokines in keratinocytes in atopic dermatitis - Manipulation by the electromagnetic field.","date":"2018","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/30286163","citation_count":21,"is_preprint":false},{"pmid":"18163957","id":"PMC_18163957","title":"Correlation between expression of DcR3 on tumor cells and sensitivity to FasL.","date":"2007","source":"Cellular & molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18163957","citation_count":21,"is_preprint":false},{"pmid":"27682872","id":"PMC_27682872","title":"Successful TB treatment induces B-cells expressing FASL and IL5RA mRNA.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27682872","citation_count":20,"is_preprint":false},{"pmid":"33586426","id":"PMC_33586426","title":"Microfluidic Tumor Vasculature Model to Recapitulate an Endothelial Immune Barrier Expressing FasL.","date":"2021","source":"ACS biomaterials science & engineering","url":"https://pubmed.ncbi.nlm.nih.gov/33586426","citation_count":20,"is_preprint":false},{"pmid":"15948252","id":"PMC_15948252","title":"Adenovirus-mediated FasL gene transfer into human gastric carcinoma.","date":"2005","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/15948252","citation_count":19,"is_preprint":false},{"pmid":"16595663","id":"PMC_16595663","title":"Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling: role of DNA methylation and protein acetylation suggest distinct mechanisms of transcriptional repression.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16595663","citation_count":18,"is_preprint":false},{"pmid":"31782491","id":"PMC_31782491","title":"Prostaglandin E1 protects cardiomyocytes against hypoxia-reperfusion induced injury via the miR-21-5p/FASLG axis.","date":"2019","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/31782491","citation_count":18,"is_preprint":false},{"pmid":"19807924","id":"PMC_19807924","title":"Identification of SH3 domain interaction partners of human FasL (CD178) by phage display screening.","date":"2009","source":"BMC immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19807924","citation_count":18,"is_preprint":false},{"pmid":"20675370","id":"PMC_20675370","title":"FasL expression in activated T lymphocytes involves HuR-mediated stabilization.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20675370","citation_count":18,"is_preprint":false},{"pmid":"20406899","id":"PMC_20406899","title":"FasL gene knock-down therapy enhances the antiglioma immune response.","date":"2010","source":"Neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/20406899","citation_count":18,"is_preprint":false},{"pmid":"23280017","id":"PMC_23280017","title":"Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis.","date":"2012","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23280017","citation_count":18,"is_preprint":false},{"pmid":"22014664","id":"PMC_22014664","title":"The expression of Fas/FasL and apoptosis in yak placentomes.","date":"2011","source":"Animal reproduction science","url":"https://pubmed.ncbi.nlm.nih.gov/22014664","citation_count":17,"is_preprint":false},{"pmid":"10899765","id":"PMC_10899765","title":"Expression of FasL and Fas protein and their soluble form in patients with hypersensitivity pneumonitis.","date":"2000","source":"International archives of allergy and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10899765","citation_count":17,"is_preprint":false},{"pmid":"32546562","id":"PMC_32546562","title":"Associations of serum soluble Fas and Fas ligand (FasL) with outcomes in systemic lupus erythematosus.","date":"2020","source":"Lupus science & medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32546562","citation_count":17,"is_preprint":false},{"pmid":"19146781","id":"PMC_19146781","title":"FAS and FASLG polymorphisms and susceptibility to idiopathic azoospermia or severe oligozoospermia.","date":"2009","source":"Reproductive biomedicine online","url":"https://pubmed.ncbi.nlm.nih.gov/19146781","citation_count":16,"is_preprint":false},{"pmid":"33841416","id":"PMC_33841416","title":"Fas/FasL Signaling Regulates CD8 Expression During Exposure to Self-Antigens.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33841416","citation_count":16,"is_preprint":false},{"pmid":"23017670","id":"PMC_23017670","title":"CD4+ CD25+ Foxp3+ IFNγ+ CD178+ human induced Treg (iTreg) contribute to suppression of alloresponses by apoptosis of responder cells.","date":"2012","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23017670","citation_count":16,"is_preprint":false},{"pmid":"21808135","id":"PMC_21808135","title":"Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma.","date":"2011","source":"The Indian journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/21808135","citation_count":15,"is_preprint":false},{"pmid":"21879377","id":"PMC_21879377","title":"Evaluation of apoptosis-related gene Fas (CD95) and FasL (CD178) polymorphisms in Iranian rheumatoid arthritis patients.","date":"2011","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/21879377","citation_count":15,"is_preprint":false},{"pmid":"16441482","id":"PMC_16441482","title":"Study of Fas (CD95) and FasL (CD178) polymorphisms in liver transplant recipients.","date":"2006","source":"Tissue antigens","url":"https://pubmed.ncbi.nlm.nih.gov/16441482","citation_count":15,"is_preprint":false},{"pmid":"23534738","id":"PMC_23534738","title":"Effects of FasL expression in oral squamous cell cancer.","date":"2013","source":"Asian Pacific journal of cancer prevention : APJCP","url":"https://pubmed.ncbi.nlm.nih.gov/23534738","citation_count":15,"is_preprint":false},{"pmid":"20394629","id":"PMC_20394629","title":"Functional polymorphisms of the FAS/FASLG genes are associated with risk of alopecia areata in a Chinese population: a case-control analysis.","date":"2010","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20394629","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49437,"output_tokens":6106,"usd":0.119951,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14946,"output_tokens":4835,"usd":0.097803,"stage2_stop_reason":"end_turn"},"total_usd":0.217754,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1995,\n      \"finding\": \"Receptor crosslinking of T-cell hybridomas induces Fas ligand (FasL) expression and upregulates Fas, and the ensuing engagement of Fas by FasL activates the programmed cell death programme; a soluble Fas-immunoglobulin fusion protein selectively blocks cell death but not activation, establishing FasL/Fas interaction as the molecular mechanism of activation-induced T-cell death (AICD).\",\n      \"method\": \"Soluble Fas-Ig fusion protein blockade, receptor crosslinking assays, T-cell hybridoma death assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal functional rescue with soluble decoy receptor, highly replicated finding, foundational mechanistic paper\",\n      \"pmids\": [\"7530337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ADAM10 (a disintegrin and metalloprotease) mediates proteolytic shedding of FasL from the cell surface, generating soluble FasL (sFasL) and membrane-bound N-terminal fragments; ADAM10 inhibition elevates FasL surface expression and increases both cytotoxic killing capacity and AICD in primary human T cells.\",\n      \"method\": \"Pharmacological inhibition, in vitro cleavage assays, loss- and gain-of-function studies in murine embryonic fibroblasts (MEFs), primary human T cell experiments\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro cleavage assay combined with genetic KO/KI and pharmacological inhibition in multiple cell types, single lab with orthogonal methods\",\n      \"pmids\": [\"17290285\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"The cytosolic polyproline region of CD95L (FasL/CD178) interacts via SH3 domain binding with Grb2, FBP17, and PACSIN2 in T-cell lysates; these interactions are abolished by mutation of the respective SH3 domains and may regulate FasL trafficking and directed expression.\",\n      \"method\": \"Peptide pulldown from T-cell lysates, peptide mass fingerprinting, co-precipitation with overexpressed constructs, SH3 domain mutagenesis\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-precipitation and mutagenesis in overexpression system, single lab, two orthogonal methods (mass fingerprint + co-IP with mutagenesis)\",\n      \"pmids\": [\"12023017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Phage display screening of a human SH3 domain library identified Tec kinases and sorting nexins as novel interaction partners of the FasL intracellular proline-rich region; interactions were verified by cellular pulldown experiments.\",\n      \"method\": \"SH3 domain phage display library screening, cellular pulldown assays\",\n      \"journal\": \"BMC immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — phage display plus confirmatory pulldown, single lab, two methods\",\n      \"pmids\": [\"19807924\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FasL palmitoylation within its transmembrane domain is critical for efficient FasL-mediated killing and for FasL processing by ADAM10; FasL processing occurs preferentially within cholesterol/sphingolipid-rich membrane nanodomains (lipid rafts), and Fas–FasL contact is required for efficient processing.\",\n      \"method\": \"Palmitoylation assays, ADAM10 cleavage assays, lipid raft fractionation, functional cytotoxicity assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — palmitoylation and membrane fractionation with functional readout, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21368861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"ERK5 activation promotes cell survival by downregulating FasL expression via a mechanism involving PKB-dependent inhibition of the Forkhead transcription factor Foxo3a; loss of ERK5 or MEK5 leads to increased Foxo3a activity and elevated FasL expression that acts as a positive feedback loop enhancing apoptosis under osmotic stress.\",\n      \"method\": \"Genetic knockout of erk5 and mek5 in fibroblasts, PKB activity assays, Foxo3a activity assays, FasL expression analysis under osmotic stress\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO with defined molecular pathway (PKB→Foxo3a→FasL), single lab, multiple methods\",\n      \"pmids\": [\"16710360\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"MEHP-induced FasL transcription in Sertoli cells is regulated through NF-κB and Sp-1 cis-regulatory elements in the FasL promoter; MEHP exposure increases sTNF-α production, which activates NF-κB and Sp-1 via TNFR1 on Sertoli cells, causing robust FasL upregulation and germ cell apoptosis in a feed-forward mechanism.\",\n      \"method\": \"Serial deletion FasL promoter-luciferase assays, site-directed mutagenesis, EMSA, chromatin immunoprecipitation, in vitro and in vivo siRNA/TNF-α neutralization experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — promoter deletion + site-directed mutagenesis + EMSA + ChIP + in vivo/in vitro functional assays, single lab with multiple orthogonal rigorous methods\",\n      \"pmids\": [\"17192273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"The glucocorticoid receptor (GR) represses the human FasL promoter by binding to a negative glucocorticoid response element at position -990 that overlaps an NF-κB binding site, competing sterically with NF-κB for DNA binding; this represents a DNA binding-dependent mechanism of GR repression distinct from transrepression.\",\n      \"method\": \"Promoter-reporter assays, in vitro DNA binding assays, chromatin context binding assays, competition binding experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro DNA binding plus chromatin-context competition assay plus reporter assays, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"16770006\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Active transcription of the FASLG/CD178/TNFSF6 gene in T lymphocytes requires chromatin remodeling at a hypersensitive site (HSS1, -189 to +185), where two precisely positioned nucleosomes are displaced; HSS1 remodeling precedes detectable FasL mRNA accumulation and is blocked by cycloheximide, indicating it is a primary regulatory event independent of DNA methylation or histone deacetylation at this locus.\",\n      \"method\": \"Indirect end-labeling, DNase I hypersensitivity mapping, micrococcal nuclease and restriction enzyme digestion, cycloheximide inhibition, primary and leukemia T cell comparisons\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — chromatin structure analysis with multiple nuclease probes and functional correlation, single lab\",\n      \"pmids\": [\"16595663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"FasL mRNA is stabilized in activated T cells through binding of the RNA-binding protein HuR to two AU-rich elements (AREs) in the FasL 3'-UTR; HuR knockdown prevents PMA-induced expression of a GFP reporter fused to the FasL 3'-UTR, demonstrating posttranscriptional regulation of FasL by HuR.\",\n      \"method\": \"Sequence analysis of 3'-UTR, in vitro and ex vivo RNA-protein interaction assays (RIP), HuR knockdown in HEK293 cells, GFP-reporter fused to FasL 3'-UTR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-binding assay in vitro and ex vivo plus functional reporter knockdown, single lab, two orthogonal methods\",\n      \"pmids\": [\"20675370\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structure of human FasL in complex with its decoy receptor DcR3 was determined; structure-informed mutations and native glycosylation of recombinant FasL reduce aggregation tendency and significantly enhance FasL-induced apoptosis in Jurkat cells, revealing how aggregation state modulates FasL activity.\",\n      \"method\": \"X-ray crystallography, recombinant protein production, site-directed mutagenesis, Jurkat cell apoptosis assays\",\n      \"journal\": \"Structure\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure combined with structure-guided mutagenesis and functional apoptosis assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"27806260\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"ERα signaling in osteoblasts induces upregulation of MMP3 expression; MMP3 cleaves and solubilizes membrane-bound FasL, and the released soluble FasL induces osteoclast apoptosis; MMP3 inhibition blocks FasL cleavage and osteoclast apoptosis, and ERα-KO osteoblasts show decreased MMP3 but not MMP7 or ADAM10 expression.\",\n      \"method\": \"EGFP-FasL cleavage assays, MMP3-specific inhibitors, siRNA knockdown of MMP3, ERα-KO mouse-derived osteoblasts, calvarial organ culture, conditioned media soluble FasL ELISA, osteoblast-osteoclast co-culture\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — multiple orthogonal methods (siRNA, KO, inhibitors, ELISA, co-culture) in primary cells and organ culture, single lab\",\n      \"pmids\": [\"22927007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FasL on platelets directly interacts with FasR (CD95) on red blood cells (RBCs), causing phosphatidylserine (PS) externalization on RBC membranes; this enhances thrombin generation and thrombus formation. Genetic deletion or inhibition of FasL reduces PS exposure, thrombin generation, and arterial thrombosis in vivo.\",\n      \"method\": \"FasL-/- and FasR-/- mouse models, in vitro platelet-RBC interaction assays, carotid artery injury model, IVC ligation model, flow cytometry, human surgical specimens\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO in multiple in vivo thrombosis models plus in vitro mechanistic assays, replicated across multiple experimental systems\",\n      \"pmids\": [\"29952767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"FADD and Caspase-8 are essential for FasL-induced apoptosis in glioma cells; one sensitive glioma line (D270) can be protected by anti-apoptotic Bcl-2 family members (type II behavior) while another (D645) cannot (type I behavior), demonstrating that FasL-induced apoptosis can proceed via Bcl-2-dependent or Bcl-2-independent pathways depending on cell type.\",\n      \"method\": \"Panel of seven glioma cell lines, FasL and TRAIL treatment, caspase inhibitor analysis, Bcl-2 overexpression protection assays, cycloheximide sensitization\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic overexpression plus pathway inhibition across multiple cell lines, single lab\",\n      \"pmids\": [\"11593384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"TGF-β3 signaling through Tgfβr2 in the medial edge epithelium (MEE) is required upstream of the FasL-Fas-Caspase extrinsic apoptosis pathway during palatal fusion; inhibition of the FasL-Fas system prevents MEE disappearance and caspase activity, while ectopic FasL rescues apoptosis in Tgfbr2-deficient MEE.\",\n      \"method\": \"Tgf-β3 and Tgfbr2 conditional knockout mice, FasL/Fas inhibition in palatal organ culture, ectopic FasL protein rescue experiment, caspase activity assays\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (KO + rescue), single lab, multiple methods\",\n      \"pmids\": [\"21593251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Antigen-specific cytotoxicity of invariant NKT (iNKT) cells in vivo depends almost exclusively on CD95 (Fas)/CD178 (FasL) interaction, correlating with CD1d expression level and TCR affinity for the target glycolipid; this is distinct from NK cells which rely primarily on perforin/granzyme mechanisms.\",\n      \"method\": \"In vivo cytotoxicity assays in mice, genetic deficiency models (FasL-deficient gld mice), tumor protection experiments, in vitro cytotoxicity with spleen/liver/thymus iNKT cells\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic deficiency model with functional cytotoxicity readout, single lab\",\n      \"pmids\": [\"20660713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Neurons express FasL protein and mRNA; neuronal FasL induces apoptosis of co-cultured CD4+ encephalitogenic T cells, and antibodies blocking neuronal FasL protect T cells from death in co-culture, identifying neuronal FasL as a mechanism for eliminating inflammatory T cells in neuroinflammation.\",\n      \"method\": \"In situ hybridization, immunohistochemistry, hippocampal neuron/T-cell co-culture, FasL-blocking antibody experiments\",\n      \"journal\": \"Brain pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — blocking antibody rescue in co-culture plus in vivo localization, single lab\",\n      \"pmids\": [\"10885654\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Human B cell-derived lymphoblastoid cell lines (LCL) constitutively produce FasL retained intracellularly in secretory lysosomes and secreted via exosomes as MHCII+FasL+ vesicles; these LCL-derived exosomes induce antigen-specific apoptosis in autologous CD4+ T cells.\",\n      \"method\": \"Flow cytometry, bead-based exosome capture assay, two independent apoptosis assays with LCL-derived exosomes and autologous CD4+ T cells\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — exosome isolation with functional apoptosis assay confirmed by two independent methods, single lab\",\n      \"pmids\": [\"24765093\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"High-dose osteocalcin (GluOC) activates GPRC6A→cAMP→PKA→CREB→p300→FoxO1 signaling, leading to FasL upregulation at the plasma membrane of adipocytes; FasL engagement of Fas on neighboring adipocytes triggers MLKL phosphorylation/homotrimerization and necroptosis.\",\n      \"method\": \"Signaling pathway dissection (CREB/p300/FoxO1 activation assays), FasL expression and membrane localization analysis, MLKL phosphorylation and homotrimerization assays, 3T3-L1 adipocyte model\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — defined signaling pathway with multiple downstream readouts, single lab, multiple biochemical assays\",\n      \"pmids\": [\"30546087\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DNA origami nanoagents presenting FasL in a hexagonal arrangement with 10 nm inter-molecular spacing mimic the predicted hexagonal DISC architecture and induce fastest and most efficient apoptosis signaling; reduced FasL number, altered spacing, or increased coupling flexibility impairs signaling, defining molecular geometry requirements for FasL-mediated death receptor activation.\",\n      \"method\": \"DNA origami scaffold engineering with defined FasL arrangements, cell apoptosis kinetics assays, comparison of geometric configurations\",\n      \"journal\": \"Small\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — reconstituted nanoscale signaling platform with systematic geometric variation and functional readout, single lab\",\n      \"pmids\": [\"34057291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Complete FasL deficiency due to a homozygous null FASLG mutation (F87fs×95) causes autoimmune lymphoproliferative syndrome (ALPS) with absent plasma FasL, normal FAS-induced apoptosis, and defective reactivation-induced cell death, establishing that FasL is non-redundantly required for AICD in vivo.\",\n      \"method\": \"FASLG gene sequencing, Western blotting for FasL expression, FAS-induced apoptosis assay, reactivation-induced cell death (AICD) test, plasma FasL ELISA\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human loss-of-function with multiple orthogonal assays and clear functional consequence, replicated pattern with prior mouse gld data\",\n      \"pmids\": [\"22857792\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Downregulation of FasL surface expression on activated T cells proceeds via endocytosis (not metalloprotease shedding in this context); cytochalasin, sodium azide, deoxyglucose, and low temperature (endocytosis inhibitors) prevented FasL loss, while the metalloprotease inhibitor KB8301 had no effect on FasL loss or AICD in these T cells.\",\n      \"method\": \"Flow cytometry of FasL surface expression, endocytosis inhibitors, metalloprotease inhibitor KB8301, IL-2-stimulated T cells\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with multiple inhibitor classes, single lab\",\n      \"pmids\": [\"11529932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"HBx activates FasL expression and mediates HepG2 cell apoptosis through a MLK3→MKK7→JNK signaling module; JNK inhibitor SP600125 and MLK3 inhibitor K252a each blocked FasL upregulation and reduced apoptosis in HBx-expressing cells.\",\n      \"method\": \"HBx expression vector transfection, siRNA knockdown, Western blotting for FasL and signaling intermediates, JNK and MLK3 inhibitors, apoptosis rate measurement\",\n      \"journal\": \"World journal of gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis with specific kinase inhibitors and genetic KD, single lab\",\n      \"pmids\": [\"22509080\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TNFα sensitizes hepatocytes to FasL-induced apoptosis by transcriptionally upregulating Fas surface expression via the NF-κB pathway (p65 subunit); genetic deletion, dominant-negative inhibition, or shRNA knockdown of p65 reduces Fas expression and prevents TNFα-induced sensitization to FasL-mediated cell death both in vitro and in vivo (via hydrodynamic p65 shRNA injection).\",\n      \"method\": \"Primary hepatocytes and cell lines, p65 genetic knockout, dominant-negative inhibition, shRNA knockdown, hydrodynamic tail vein injection in mice, Fas surface expression assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion plus dominant-negative plus shRNA confirmed both in vitro and in vivo, multiple orthogonal approaches\",\n      \"pmids\": [\"30185788\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FASLG (FasL/CD178/CD95L) is a type II transmembrane protein of the TNF superfamily that induces apoptosis in Fas (CD95)-bearing target cells; its surface expression is tightly regulated by ADAM10-mediated ectodomain shedding (modulated by palmitoylation and lipid raft localization), endocytic internalization, transcriptional control through NF-κB, Sp-1, and GR competing at the promoter, and post-transcriptional stabilization by HuR; its intracellular polyproline region serves as a docking platform for SH3-domain proteins (Grb2, FBP17, PACSIN2, Tec kinases, sorting nexins) that regulate its trafficking and potential reverse signaling; optimal FasL-induced DISC assembly requires hexagonal receptor geometry at ~10 nm spacing; proteases MMP3 and ADAM10 generate soluble FasL that can trigger osteoclast and other cell apoptosis; FasL mediates AICD of T cells, iNKT cytotoxicity, neuronal elimination of inflammatory T cells, and platelet-RBC procoagulant signaling, and complete loss-of-function mutations cause autoimmune lymphoproliferative syndrome in humans.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FASLG (FasL/CD178/CD95L) is a type II transmembrane TNF-superfamily ligand that triggers apoptosis in Fas-bearing cells and is the non-redundant effector of activation-induced cell death (AICD) in T lymphocytes [#0, #20]; its homozygous null mutation causes human autoimmune lymphoproliferative syndrome with intact Fas-induced apoptosis but defective reactivation-induced death [#20]. Productive death-signaling depends on ligand geometry: hexagonal FasL presentation at ~10 nm spacing drives fastest DISC-mediated apoptosis, and reduced ligand number or altered spacing impairs signaling [#19], while aggregation state (modulated by glycosylation and the decoy receptor DcR3) tunes apoptotic potency [#10]. Downstream, FADD and caspase-8 execute killing, which proceeds through Bcl-2-dependent (type II) or Bcl-2-independent (type I) routes depending on target cell [#13]. FasL surface availability is governed by proteolytic shedding by ADAM10 — favored within palmitoylation-dependent lipid-raft nanodomains and requiring Fas–FasL contact — which generates soluble FasL and limits cytotoxicity and AICD [#1, #4], by an alternative MMP3-mediated cleavage downstream of osteoblast ERα signaling that solubilizes FasL to kill osteoclasts [#11], and by endocytic internalization independent of metalloprotease shedding [#21]. Expression is controlled at multiple levels: chromatin remodeling at the HSS1 promoter site [#8], transcriptional activation through NF-κB and Sp-1 and repression by the glucocorticoid receptor competing for an overlapping site [#6, #7], and post-transcriptional stabilization of FasL mRNA by HuR at 3'-UTR AU-rich elements [#9]. Beyond classical cytotoxicity, FasL mediates iNKT-cell killing [#15], neuronal elimination of inflammatory T cells [#16], exosome-delivered apoptosis of CD4+ T cells [#17], adipocyte necroptosis [#18], and platelet–red-blood-cell procoagulant signaling that promotes thrombosis [#12]. The intracellular polyproline region binds SH3-domain proteins (Grb2, FBP17, PACSIN2, Tec kinases, sorting nexins), implicated in trafficking and potential reverse signaling [#2, #3].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established that FasL engagement of Fas is the molecular trigger of activation-induced T-cell death, defining the ligand-receptor axis underlying peripheral immune homeostasis.\",\n      \"evidence\": \"Soluble Fas-Ig decoy blockade and receptor crosslinking in T-cell hybridoma death assays\",\n      \"pmids\": [\"7530337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the structural geometry of receptor engagement\", \"Did not address regulation of FasL surface levels\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Extended FasL effector function beyond lymphocytes by showing neurons use FasL to kill encephalitogenic T cells, framing FasL as a tissue immune-privilege mechanism.\",\n      \"evidence\": \"In situ hybridization, IHC, and FasL-blocking antibody rescue in neuron/T-cell co-culture\",\n      \"pmids\": [\"10885654\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-culture model, not in vivo neuroinflammation\", \"Mechanism of neuronal FasL regulation not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Resolved that downstream apoptosis requires FADD and caspase-8 and can be Bcl-2-dependent or independent, defining type I/type II FasL death pathways.\",\n      \"evidence\": \"Glioma cell-line panel with Bcl-2 overexpression and caspase inhibition\",\n      \"pmids\": [\"11593384\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-type basis for type I vs type II behavior not molecularly explained\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Identified endocytosis, rather than metalloprotease shedding, as a route for FasL surface downregulation in activated T cells, revealing context-specific control of ligand availability.\",\n      \"evidence\": \"Endocytosis vs metalloprotease inhibitor panel on IL-2-stimulated T cells, flow cytometry\",\n      \"pmids\": [\"11529932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Endocytic machinery not identified\", \"Apparent conflict with later ADAM10 shedding data unresolved by context\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Showed the intracellular polyproline region of FasL recruits SH3-domain adaptors, opening the possibility of trafficking control and reverse signaling.\",\n      \"evidence\": \"Peptide pulldown, mass fingerprinting, and SH3 mutagenesis in T-cell lysates/overexpression\",\n      \"pmids\": [\"12023017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Overexpression-based interactions\", \"Functional consequence for trafficking not demonstrated\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped multiple transcriptional and chromatin control points (HSS1 remodeling, NF-κB/Sp-1 activation, GR repression, ERK5/Foxo3a) defining how FasL expression is set.\",\n      \"evidence\": \"Promoter-reporter, EMSA, ChIP, nucleosome mapping, and kinase/transcription-factor genetic perturbation across multiple systems\",\n      \"pmids\": [\"16595663\", \"17192273\", \"16770006\", \"16710360\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Largely single-system promoter studies\", \"Cross-talk integration among these inputs not established\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Identified ADAM10 as the protease shedding FasL, establishing that ectodomain cleavage limits cytotoxic and AICD activity.\",\n      \"evidence\": \"In vitro cleavage, MEF KO/KI, pharmacological inhibition, primary human T cells\",\n      \"pmids\": [\"17290285\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define spatial/membrane control of cleavage\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Linked FasL palmitoylation and lipid-raft localization to ADAM10 processing and killing efficiency, and added HuR-mediated mRNA stabilization as a post-transcriptional control.\",\n      \"evidence\": \"Palmitoylation/raft fractionation with cytotoxicity assays; RIP and 3'-UTR reporter with HuR knockdown\",\n      \"pmids\": [\"21368861\", \"20675370\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Palmitoyltransferase not identified\", \"HuR work largely in HEK293 reporter context\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Demonstrated that iNKT cytotoxicity depends almost exclusively on the Fas/FasL axis, distinguishing it from perforin-based NK killing.\",\n      \"evidence\": \"In vivo cytotoxicity in FasL-deficient gld mice with tumor protection assays\",\n      \"pmids\": [\"20660713\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of FasL polarization at the iNKT synapse not addressed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Placed FasL-Fas-caspase apoptosis downstream of TGF-β3/Tgfbr2 signaling in epithelial fusion, showing a developmental role via genetic epistasis.\",\n      \"evidence\": \"Tgfbr2 conditional KO with FasL/Fas inhibition and ectopic FasL rescue in palatal organ culture\",\n      \"pmids\": [\"21593251\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Transcriptional link from TGF-β3 to FasL not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the definitive human genetic proof that FasL is non-redundantly required for AICD, as null mutation causes ALPS with defective reactivation-induced death.\",\n      \"evidence\": \"FASLG sequencing, Western blot, FAS-induced apoptosis and AICD assays, plasma FasL ELISA in patient\",\n      \"pmids\": [\"22857792\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Single homozygous case\", \"Does not address partial loss-of-function phenotypes\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified MMP3 as an ERα-induced alternative protease that solubilizes FasL to drive osteoclast apoptosis, broadening the proteolytic regulation of FasL beyond ADAM10.\",\n      \"evidence\": \"EGFP-FasL cleavage, MMP3 inhibitors/siRNA, ERα-KO osteoblasts, co-culture and soluble FasL ELISA\",\n      \"pmids\": [\"22927007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of MMP3 vs ADAM10 across tissues unclear\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed FasL is delivered via exosomes as MHCII+FasL+ vesicles capable of antigen-specific T-cell killing, adding a secreted delivery mode.\",\n      \"evidence\": \"Flow cytometry, bead-based exosome capture, two apoptosis assays with LCL exosomes and autologous CD4+ T cells\",\n      \"pmids\": [\"24765093\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of exosomal FasL not established\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Determined the FasL–DcR3 structure and showed aggregation state controls apoptotic potency, connecting molecular architecture to activity.\",\n      \"evidence\": \"X-ray crystallography with structure-guided mutagenesis and Jurkat apoptosis assays\",\n      \"pmids\": [\"27806260\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not directly resolve the apoptosis-competent membrane DISC geometry\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Expanded FasL into procoagulant and metabolic biology—platelet FasL drives RBC PS exposure and thrombosis, and osteocalcin-induced FasL triggers adipocyte necroptosis—and showed TNFα/NF-κB sensitizes hepatocytes by upregulating Fas.\",\n      \"evidence\": \"FasL/FasR KO thrombosis models, GPRC6A→CREB→FoxO1 signaling with MLKL readouts, p65 genetic/shRNA perturbation in hepatocytes in vitro and in vivo\",\n      \"pmids\": [\"29952767\", \"30546087\", \"30185788\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Diverse systems with limited cross-validation\", \"Switch between apoptotic and necroptotic outcomes not mechanistically unified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined the molecular geometry requirements for FasL signaling, showing hexagonal ~10 nm ligand spacing maximizes apoptosis, linking nanoscale ligand arrangement to DISC assembly.\",\n      \"evidence\": \"DNA origami scaffolds with systematic FasL spacing/number variation and apoptosis kinetics\",\n      \"pmids\": [\"34057291\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Predicted hexagonal DISC architecture inferred functionally, not structurally observed in cells\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the competing fates of FasL — surface presentation, ADAM10/MMP3 shedding, endocytosis, and exosomal export — are integrated in a single cell to set output (apoptosis vs necroptosis vs reverse signaling) remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model coordinating trafficking, cleavage, and SH3-adaptor reverse signaling\", \"Physiological role of intracellular polyproline interactions undemonstrated\", \"Determinants selecting apoptotic vs necroptotic downstream outcome unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [0, 10, 19]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [1, 4, 18, 21]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [0, 13, 18]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 15, 16, 20]},\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [12]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [6, 7, 8]}\n    ],\n    \"complexes\": [\"DISC\"],\n    \"partners\": [\"FAS\", \"ADAM10\", \"MMP3\", \"DcR3\", \"Grb2\", \"FBP17\", \"PACSIN2\", \"HuR\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}